A number of surgical procedures have been reported as initial treatments for skin avulsion injuries of the extremities, including simultaneous skin grafting using the avulsed skin^[@R1]^ and revascularization of the avulsed tissue under microscopy.^[@R2]^ As this type of injury can occur at various sites and in various forms, the viability of avulsed skin can be difficult to evaluate, and in many cases, the avulsed skin shows necrosis after initial surgery.^[@R3]^ Basic fibroblast growth factor (bFGF) dates back to 1974, when Gospodarowicz^[@R4]^ discovered a protein that promotes fibroblast growth from the bovine pituitary gland. This was followed by the development and commercialization of genetically engineered recombinant bFGF for the treatment of skin ulcer (Fiblast Spray; Kaken Pharmaceutical, Tokyo, Japan), which is clinically used in Japan. bFGF has been shown to be extremely useful for the treatment of skin ulcer,^[@R5]^ and its indications are expanding to include a combination therapy with artificial dermis^[@R6]^ and the treatment of second-degree burn injury.^[@R7]^ This report describes a surgical procedure using bFGF applied to a full-thickness skin graft for the treatment of skin avulsion injuries of the extremities.

MATERIALS AND METHODS
=====================

The present surgical technique was applied to skin avulsion injuries of the upper and lower extremities on the day of injury under general anesthesia. Avulsed skin in the wound was turned over while retaining its continuity, and the contaminated subcutaneous fat tissue on the inside of skin was removed with scissors from the distal to proximal ends of the skin. During fat tissue removal, bleeding from the subdermal vascular plexus was observed, indicating intact blood supply. After the avulsed skin was processed into a full-thickness skin graft, several drainage holes (5--10 mm in diameter) were made on the graft with a no. 11 scalpel for drainage from the graft bed and to prevent the formation of seroma and hematoma. The avulsed skin was used in its entirely whenever possible, regardless of the degree of damage. After the graft was immediately debrided, genetically recombinant human bFGF (100 μg/mL; Fiblast Spray) was sprayed at a dose of 1 μg/cm^2^ onto the graft bed. After 30 seconds, the graft bed was covered with the full-thickness skin graft and sutured. Postoperatively, pressure immobilization with ointment gauzes and elastic bandages was administered for 1 week. In addition, the surface areas of the skin graft that did not successfully take were scraped away carefully, preserving as much as possible the revascularized dermal component. bFGF was sprayed again onto the generated raw surface to promote epithelialization. Rehabilitation programs were gradually started 2 weeks postoperatively to prevent joint contracture.

CLINICAL CASES
==============

The author applied the present surgical technique to skin avulsion injuries in 9 patients (age range, 8--65 years), including 5 patients with upper and 4 patients with lower extremity injuries. All patients were followed on an outpatient basis for 1 year postoperatively. After surgery, although the full-thickness skin grafts were partially ulcerated, the wounds healed with conservative therapy. There were no limitations in joint range of motion due to contracture, and cosmetic outcomes were favorable.

Case 1
------

A 64-year-old man collided with a guardrail while operating a 2-wheel vehicle and suffered skin avulsion injury over the dorsum of the right foot. Surgery was performed on the day of the accident with present technique (Fig. [1](#F1){ref-type="fig"}A). Despite partial ulcer formation, the grafted skin healed with conservative treatment alone. Surgical outcome at 6 months postoperatively was excellent from a cosmetic standpoint, and range of joint motion was not limited due to contracture (Fig. [1](#F1){ref-type="fig"}B).

![Case 1: Intraoperative findings (A): Although the avulsed skin partly retained an attachment along the lateral aspect of the right foot, the skin was separated from the fascia of the muscle over a wide area. After removing contaminated subcutaneous tissue, a no. 11 scalpel was used to create multiple drainage holes through the avulsed skin. Following debridement of the contaminated tissue, basic fibroblast growth factor was sprayed over the graft bed and the graft bed was covered with the full-thickness skin graft. B, Postoperative findings at 6 months. The skin graft scar was flexible, soft, and without scar contracture or limitation in joint range of motion. Cosmetic outcome was favorable.](gox-3-e371-g001){#F1}

Case 2
------

A 37-year-old man had his right arm drawn into a roller machine and presented with skin avulsion injury of the right forearm. Surgery was performed on the day of the accident with present technique (Fig. [2](#F2){ref-type="fig"}A). Although edema formation extending distally from the skin avulsion injury was noted immediately after surgery, it gradually resolved after active rehabilitation started 2 weeks postoperatively. At 1 year postoperatively, the skin graft scar was flexible and soft with no scar contracture of the sutured wound and no limitation in the joint range of motion (Fig. [2](#F2){ref-type="fig"}B).

![Case 2: Intraoperative findings (A): The skin of the right forearm was avulsed circumferentially from the elbow to wrist, in some parts along with the fascia, with the continuity of the skin maintained only at the distal portion. The avulsed skin was turned over while retaining its continuity and was crushed from the distal to proximal ends of the skin. Contaminated subcutaneous fat tissue was removed with scissors, and the graft bed was covered with the full-thickness skin graft and sutured after spraying with basic fibroblast growth factor. B, Postoperative findings at 1 year. The skin graft scar was flexible and soft, with no scar contracture or limitation in joint range of motion. Cosmetic outcome was also favorable without pigmentation or decolorization.](gox-3-e371-g002){#F2}

DISCUSSION
==========

bFGF used in the present technique would have stimulated vascular endothelial cells and epidermal cells to promote angiogenesis, granulation tissue formation, and epithelialization,^[@R5]^ and bFGF was also recently shown to improve the quality of the scars formed as a result of epithelialization, by preventing hypertrophic scar formation and scar contracture.^[@R8]^ bFGF is considered to exert these effects by promoting (1) the proliferation of fibroblasts during the proliferation phase and (2) the apoptosis of fibroblasts and myofibroblasts, thereby decreasing their numbers during the reconstruction phase and preventing excessive wound constriction.^[@R9]^ Akita et al^[@R7]^ also reported that bFGF use in skin grafting for burn wounds resulted in the formation of a softer skin graft scar.^[@R10]^ The author has experience of treating injuries similar to those of the patients described here with a full-thickness skin graft prepared from the avulsed skin, but partial necrosis of the graft often occurred. In the present cases, the use of bFGF in combination with skin grafting improved both (1) the viability of the avulsed skin that was damaged to various degrees and (2) the quality of the skin and the marginal scar.

The intraoperative use of bFGF is expected to improve the engraftment rate of full-thickness skin grafts, reduce time to wound closure, bring forward the rehabilitation schedule, and prevent postoperative motor dysfunction. The author previously reported that a bFGF drug delivery system greatly facilitated peripheral regeneration.^[@R11]^ Although the recovery of sensory perception in the avulsed skin was not examined in the present study, the use of bFGF in skin avulsion injuries may facilitate the recovery of the neural networks in the damaged subcutaneous tissue.

CONCLUSION
==========

Skin avulsion injuries of the extremities were treated with bFGF in combination with full-thickness skin grafting using the avulsed skin. The procedure was effective in preventing ulcer formation and scar contracture postoperatively and resulted in wound healing with the formation of a good-quality, flexible scar.
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